abstract |
A composition containing an amount of 40 mg of an isolated human anti-TNF antibody, for use in the treatment of an autoimmune disorder in a human subject, where the composition is to be administered subcutaneously to the human subject in need according to a regimen of biweekly dosage every 13-15 days, and where the human anti-TNF antibody neutralizes the cytotoxicity of human TNF in a standard in vitro L929 assay with an IC50 of 1 x 10-9 M or less, comprises a light chain variable region ( LCVR) that includes a CDR3 domain that has the amino acid sequence of SEQ ID No. 3, a CDR2 domain that has the amino acid sequence of SEQ ID No. 5 and a CDR1 domain that has the amino acid sequence of SEQ ID No. 7, and comprises a heavy chain variable region (HCVR) that includes a CDR3 domain having the amino acid sequence of SEQ ID No. 4, a CDR2 domain having the amino acid sequence of SEQ ID No. 6 and a CDR1 domain having the amino acid sequence of SEQ ID NO. 8. |